T. Rowe Price Associates’s Arcturus Therapeutics ARCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $516K | Buy |
|
|||||
|
2025
Q2 | $303K | Buy |
|
|||||
|
2025
Q1 | $214K | Buy |
|
|||||
|
2024
Q4 | $323K | Buy |
|
|||||
|
2024
Q3 | $412K | Buy |
|
|||||
|
2024
Q2 | $429K | Buy |
|
|||||
|
2024
Q1 | $575K | Buy |
|
|||||
|
2023
Q4 | $508K | Buy |
|
|||||
|
2023
Q3 | $402K | Sell |
|
|||||
|
2023
Q2 | $553K | Sell |
|
|||||
|
2023
Q1 | $477K | Buy |
|
|||||
|
2022
Q4 | $335K | Buy |
|
|||||
|
2022
Q3 | $271K | Buy |
|
|||||
|
2022
Q2 | $263K | Buy |
|
|||||
|
2022
Q1 | $440K | Buy |
|
|||||
|
2021
Q4 | $557K | Buy |
|
|||||
|
2021
Q3 | $704K | Sell |
|
|||||
|
2021
Q2 | $4.53M | Sell |
|
|||||
|
2021
Q1 | $7.56M | Sell |
|
|||||
|
2020
Q4 | $61.7M | Buy |
|
|||||
|
2020
Q3 | $30.2M | Buy |
|
|||||
|
2020
Q2 | $24.2M | Buy |
|